These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 18557746

  • 1. Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera.
    Cario H, Schwarz K, Herter JM, Komrska V, McMullin MF, Minkov M, Niemeyer C, Pospisilova D, Reinhard H, Debatin KM, Pahl HL.
    Br J Haematol; 2008 Aug; 142(4):622-6. PubMed ID: 18557746
    [Abstract] [Full Text] [Related]

  • 2. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V, Misurin AV, Michiels JJ, Rozenberg JM, Sokolova MA, Ivanova VL, Kolosheinova TI, Manakova TE, Levina AA, Semenova EA, Khoroshko ND.
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [Abstract] [Full Text] [Related]

  • 3. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 4. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG.
    Br J Haematol; 2005 Oct 20; 131(2):166-71. PubMed ID: 16197445
    [Abstract] [Full Text] [Related]

  • 5. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar 20; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 6. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O, Ishigami T, Adachi S, Morimoto A.
    Pediatr Blood Cancer; 2008 Dec 20; 51(6):802-5. PubMed ID: 18802948
    [Abstract] [Full Text] [Related]

  • 7. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
    Leszczynska A, Grzenkowicz-Wydra J, Chmielewska-Gorycka L, Bieniaszewska M, Hellmann A.
    Acta Haematol; 2016 Dec 20; 136(2):123-8. PubMed ID: 27410038
    [Abstract] [Full Text] [Related]

  • 8. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.
    Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC.
    Blood; 2008 Apr 01; 111(7):3863-6. PubMed ID: 18195094
    [Abstract] [Full Text] [Related]

  • 9. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.
    Steimle C, Lehmann U, Temerinac S, Goerttler PS, Kreipe H, Meinhardt G, Heimpel H, Pahl HL.
    Ann Hematol; 2007 Apr 01; 86(4):239-44. PubMed ID: 17256145
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
    Teofili L, Foà R, Giona F, Larocca LM.
    Haematologica; 2008 Feb 01; 93(2):169-72. PubMed ID: 18245648
    [No Abstract] [Full Text] [Related]

  • 12. The effect of the JAK2 V617F mutation on PRV-1 expression.
    Mnjoyan Z, Yoon D, Li J, Delhommeau F, Afshar-Kharghan V.
    Haematologica; 2006 Mar 01; 91(3):411-2. PubMed ID: 16503546
    [Abstract] [Full Text] [Related]

  • 13. Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
    Martini M, Teofili L, Larocca LM.
    Methods Mol Med; 2006 Mar 01; 125():265-73. PubMed ID: 16502591
    [Abstract] [Full Text] [Related]

  • 14. PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia.
    Passamonti F, Pietra D, Rumi E, Arcaini L, Della Porta MG, Malcovati L, Pascutto C, Lazzarino M, Cazzola M.
    Leukemia; 2005 May 01; 19(5):888-9. PubMed ID: 15744342
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Increased CD177 (PRV1) expression in thalassaemia and the underlying erythropoietic activity.
    Zoi K, Terpos E, Zoi C, Loukopoulos D.
    Br J Haematol; 2008 Apr 01; 141(1):100-4. PubMed ID: 18324972
    [Abstract] [Full Text] [Related]

  • 17. Epigenetic control of PRV-1 expression on neutrophils.
    Jelinek J, Li J, Mnjoyan Z, Issa JP, Prchal JT, Afshar-Kharghan V.
    Exp Hematol; 2007 Nov 01; 35(11):1677-83. PubMed ID: 17976520
    [Abstract] [Full Text] [Related]

  • 18. A novel JAK2 exon 12 mutation identified in the retrospective analysis of paraffin-embedded tissues of polycythemia vera patients.
    Burjanivova T, Marcinek J, Lasabova Z, Minarik G, Szepe P, Balharek T, Vanochova A, Polacek H, Plank L.
    Diagn Mol Pathol; 2009 Jun 01; 18(2):108-11. PubMed ID: 19430293
    [Abstract] [Full Text] [Related]

  • 19. High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera.
    Yeh YM, Chen YL, Cheng HY, Su WC, Chow NH, Chen TY, Ho CL.
    Am J Clin Pathol; 2010 Aug 01; 134(2):266-70. PubMed ID: 20660330
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.